Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo*
References (38)
- et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction inulcer complications: Randomised controlled trial
Lancet
(2004) - et al.
Response criteria for clinical trials on osteoarthritis of the knee and hip: A report of the Osteoarthritis Research Society International StandingCommittee for Clinical Trials Response Criteria Initiative
Osteoarthritis Cartilage
(2000) - et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET,cardiovascular outcomes: Randomised controlled trial
Lancet
(2004) - et al.
Burden of major musculoskeleta conditions
Bull World Health Organ
(2003) - et al.
Health-related quality of life among older adults with arthritis
Health Qual Life Outcomes
(2004) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update
Arthritis Rheum
(2000)- et al.
EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committeefor International Clinical Studies Including Therapeutic Trials (ESCISIT)
Ann Rheum Dis
(2003) - et al.
Update of ACR guidelines for osteoarthritis: Role of the coxibs
J Pain Symptom Manage
(2002) The role of anti-inflammatory drugs in the treatment of osteoarthritis: A European viewpoint
Clin Exp Rheumatol
(2001)The role of anti-inflammatory drugs in the treatment of osteoarthritis: A United States viewpoint
Clin Exp Rheumatol
(2001)
Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs
Am J Med
(2001)
Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
N Engl J Med
(1999)
The hidden costs of arthritis treatment and the cost of new therapy—the burden of non-steroidal antiinflammatory drug gastropathy
Rheumatology (Oxford)
(2002)
Celecoxib versus diclofenac in the management of osteoarthritis of the knee
Scand J Rheumatol
(2001)
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials
BMJ
(2002)
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: A randomized controlled trial
J Am Geriatr Soc
(2004)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
N Engl J Med
(2000)
Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic
FASEB J
(2004)
Dose escalation study to assess the safety, tolerability, pharmaco kinetics and pharmacodynamics of COX189 in healthy subjects
Ann Rheum Dis
(2002)
Cited by (61)
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review
2020, Seminars in Arthritis and RheumatismComparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: Systematic analytic review
2016, Osteoarthritis and CartilageInfluence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: A meta-analysis of randomized placebo-controlled trials
2010, Osteoarthritis and CartilageCitation Excerpt :The results of the article selection process are reported in Fig. 1. From the 343 articles identified, 33 articles were included14–46. Flare design was used in 27/33 (82%) studies.
Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?
2021, Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
- *
Data from this study were presented as a poster at the 9th World Congress on Osteoarthritis, December 2-5, 2004, Chicago, Illinois.
Copyright © 2005 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.